Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • SAR405: Selective ATP-Competitive Vps34 Inhibitor for Pre...

    2026-02-05

    SAR405: Selective ATP-Competitive Vps34 Inhibitor for Precision Autophagy Research

    Executive Summary: SAR405 is a nanomolar-potency, ATP-competitive inhibitor of Vps34, a class III phosphoinositide 3-kinase essential for autophagy regulation and vesicle trafficking (APExBIO). It demonstrates high selectivity, showing no inhibition of class I/II PI3Ks or mTOR up to 10 μM. SAR405 blocks autophagosome formation in cellular models, synergizes with mTOR inhibitors, and impairs late endosome-lysosome function (Park et al., 2023). These features establish SAR405 as a critical probe for mechanistic studies in cancer and neurodegenerative disease research. Usage parameters, solubility, and storage guidance are well-characterized for reproducible application (APExBIO).

    Biological Rationale

    Autophagy is a conserved catabolic process that recycles cytoplasmic constituents to maintain energy homeostasis and cellular integrity, especially under metabolic stress (Park et al., 2023). Vps34 (PIK3C3), the sole class III PI3K in mammals, generates phosphatidylinositol 3-phosphate (PI3P), a lipid crucial for autophagosome nucleation and endomembrane dynamics. Dysregulation of Vps34 activity disrupts vesicle trafficking, lysosomal function, and autophagic flux, which are implicated in cancer, neurodegenerative, and metabolic diseases. Research on specific inhibitors like SAR405 enables dissection of Vps34-mediated signaling, facilitating mechanistic studies and therapeutic exploration (SAR405: Precision Vps34 Inhibition extends prior workflow guidance with detailed molecular selectivity data).

    Mechanism of Action of SAR405

    SAR405 is a highly selective, ATP-competitive inhibitor of human Vps34 kinase. It binds within the ATP-binding cleft, sterically blocking access and inhibiting kinase activity. SAR405 exhibits a dissociation constant (Kd) of 1.5 nM and an IC50 of 1 nM against recombinant human Vps34 under standard kinase assay conditions (pH 7.5, 25°C, 10 mM MgCl2) (APExBIO). It does not inhibit class I or II PI3Ks, or mTOR, at concentrations up to 10 μM. Cellular studies in GFP-LC3 HeLa and H1299 lines reveal that SAR405 disrupts autophagosome formation, leads to swollen late endosome-lysosomes, and impairs cathepsin D maturation, signifying defective lysosomal function. These effects are distinct from mTOR inhibitors; SAR405 can synergize with compounds like everolimus to further suppress autophagy (SAR405 and the New Era of Precision Autophagy Inhibition further explores SAR405's impact on AMPK-ULK1 signaling and translational research).

    Evidence & Benchmarks

    • SAR405 inhibits recombinant human Vps34 with Kd = 1.5 nM and IC50 = 1 nM under standard assay conditions (APExBIO).
    • No inhibitory activity is observed for class I/II PI3Ks or mTOR at up to 10 μM, demonstrating high isoform selectivity (APExBIO).
    • In cell-based assays (GFP-LC3 HeLa, H1299), SAR405 blocks autophagosome formation and accumulation, confirming functional autophagy inhibition (Park et al., 2023).
    • SAR405 induces accumulation of swollen late endosome-lysosome compartments and defective cathepsin D maturation, indicating impaired vesicle trafficking and lysosome function (Park et al., 2023).
    • Combining SAR405 with mTOR inhibitors (e.g., everolimus) yields synergistic inhibition of autophagy, useful for dissecting pathway redundancies (Park et al., 2023).

    Applications, Limits & Misconceptions

    SAR405 is primarily applied in basic and translational research to modulate autophagy, vesicle trafficking, and lysosome function. It is used in cancer and neurodegenerative disease models to interrogate the Vps34 kinase signaling pathway and to test pharmacological interventions. SAR405's selectivity profile makes it suitable for experiments requiring precise dissection of class III PI3K function without off-target effects on class I/II PI3Ks or mTOR (SAR405: Precision Vps34 Inhibition for Autophagy Research details comparative selectivity; the present article updates with new synergy evidence and workflow integration).

    Common Pitfalls or Misconceptions

    • SAR405 does not inhibit class I or II PI3Ks, or mTOR, even at high concentrations (>10 μM); it should not be used to study these kinases.
    • It is insoluble in water and requires DMSO (preferred, >10 mM) or ethanol (with ultrasonic assistance) for preparation; improper solvent use can cause precipitation and assay failure.
    • Long-term storage of SAR405 solutions at room temperature leads to loss of potency; store stock solutions below -20°C and avoid repeated freeze-thaw cycles.
    • SAR405 blocks autophagosome formation but does not directly degrade ULK1 or AMPK; misinterpretation may arise if not paired with pathway-specific readouts (Park et al., 2023).
    • Effects in non-mammalian systems are not validated; extrapolation beyond human or standard cell models requires additional benchmarking.

    Workflow Integration & Parameters

    SAR405 (SKU A8883, APExBIO) is supplied as a lyophilized powder. Researchers should prepare stock solutions at >10 mM in DMSO or, with caution, in ethanol using ultrasonic assistance. Store aliquots at <-20°C for up to several months. For cell-based assays, dilute stocks into culture medium immediately before use, ensuring final DMSO concentrations do not exceed 0.1–0.2% v/v to avoid cytotoxicity. Standard experimental concentrations range from 10 nM to 1 μM, depending on cell line and endpoint. SAR405 can be combined with mTOR inhibitors for synergy studies. For detailed, scenario-driven protocols and troubleshooting tips, refer to SAR405: Precision Vps34 Inhibition for Reliable Autophagy Studies, which this article extends by incorporating recent mechanistic insights and updated storage guidance.

    Conclusion & Outlook

    SAR405, developed and supplied by APExBIO, is a gold-standard tool for selective ATP-competitive Vps34 inhibition. Its nanomolar potency, high isoform specificity, and well-characterized cellular effects make it indispensable for autophagy research, vesicle trafficking modulation, and lysosome function studies in advanced disease models. Benchmarks confirm robust inhibition of autophagosome formation and synergy with mTOR inhibitors, supporting both mechanistic and translational applications. As research evolves—especially with new paradigms in AMPK-ULK1 signaling (Park et al., 2023)—SAR405 will remain central to dissecting the Vps34 kinase signaling pathway and developing targeted interventions for cancer and neurodegenerative diseases. For a comprehensive exploration of SAR405’s role in integrating energy stress and autophagy control, see SAR405 and the Vps34 Kinase Pathway, which this article updates with newly validated benchmarks and workflow recommendations.